SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination...
Astellas Receives +ve Opinion for XTANDI for Early Prostate Cancer Treatment
Nanoform Announces Milestone with Promising Clinical Results for Enzalutamide
EC Approves Pfizer’s TALZENNA®with XTANDI® for Prostate Cancer
Pfizer & Astellas` XTANDI Approved by FDA in Earlier Prostate Cancer Treatment
Humanwell Puracap`s Generic Enzalutamide Receives Approval in the U.S.